FLC
MACK

Fifth Lane Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Fifth Lane Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,929
Closed -$134K – 275
2023
Q3 		$134K Hold
10,929
– – 0.05% 112
2023
Q2 		$134K Buy
+10,929
New +$137K 0.04% 111

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fifth Lane Capital's MACK Position: Q4 2023 in Review

Fifth Lane Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2023, closing a stake of 10,929 shares — an estimated $134K sold.

Fifth Lane Capital first reported a position in MACK in Q2 2023 and held it in 2 quarters. The position peaked at $134K in Q3 2023. 67 funds tracked by Wall St. Rank hold MACK as of Q4 2023.

  • Fifth Lane Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Fifth Lane Capital sold 10,929 Merrimack Pharmaceuticals, Inc. shares in Q4 2023, an estimated $134K.
  • Fifth Lane Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2023 and held it in 2 quarters.
  • Fifth Lane Capital's Merrimack Pharmaceuticals, Inc. position peaked at $134K in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2023.

Based on Fifth Lane Capital's 13F filing for Q4 2023, filed 14 Feb 2024.